OCT50

N/A

Report date: 2024/12/06 10:41:04

Base Information

Drug NameOCT50
Drug Alias NameOCT50OCT-50
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousMultiple Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOctagon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOctagon Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousMultiple Sclerosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A